 |
|
|
| |
Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
(D/C/F/TAF) in Treatment-experienced, Virologically Suppressed (EMERALD)
and Treatment-naïve (AMBER) Patients: Week 48 Subgroup Analysis by Age
|
| |
| |
Reported by Jules Levin
9TH INTERNATIONAL WORKSHOP ON HIV AND AGING;
SEPTEMBER 13-14, 2018; NEW YORK CITY, NEW YORK
Karam Mounzer,1,* Peter Shalit,2 Cristina Mussini,3 Christoph D. Spinner,4 Romana Petrovic,5 John Jezorwski,6 Keith Dunn,7 Eric Y. Wong7
1Philadelphia FIGHT, Philadelphia, PA, USA; 2Tribal Med, Seattle, WA, USA; 3University of Modena and Reggio Emilia, Modena, Italy; 4Technische Universität Munchen, Munich, Germany;
5Janssen Research & Development, Beerse, Belgium; 6Janssen Research & Development, LLC, Pennington, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
|
| |
|
|
|
|
|
